Last A$0.76 AUD
Change Today -0.02 / -2.58%
Volume 101.1K
BLT On Other Exchanges
Symbol
Exchange
OTC US
Frankfurt
OTC US
As of 12:10 AM 01/29/15 All times are local (Market data is delayed by at least 15 minutes).

benitec biopharma ltd (BLT) Snapshot

Open
A$0.78
Previous Close
A$0.78
Day High
A$0.79
Day Low
A$0.75
52 Week High
02/25/14 - A$2.38
52 Week Low
10/30/14 - A$0.52
Market Cap
87.3M
Average Volume 10 Days
184.9K
EPS TTM
A$-0.09
Shares Outstanding
115.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BENITEC BIOPHARMA LTD (BLT)

Related News

No related news articles were found.

benitec biopharma ltd (BLT) Related Businessweek News

No Related Businessweek News Found

benitec biopharma ltd (BLT) Details

Benitec Biopharma Limited, a biotechnology company, develops novel treatments for chronic and life-threatening conditions based on its gene silencing technology, DNA-directed RNA interference (ddRNAi). The company’s ddRNAi technology provides novel therapeutics to treat a range of human medical diseases and conditions, such as hepatitis C, hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer, and oculopharyngeal muscular dystrophy (OPMD). Its pipeline of in-house and partnered therapeutic programs include TT-034 for hepatitis C; Tribetarna for the treatment of chemotherapy resistant non-small cell lung cancer; Hepbarna for Hepatitis B; and Pabparna for the treatment of OPMD. The company also licenses its ddRNAi technology to biopharmaceutical companies for the clinical applications comprising HIV/AIDS, retinitis pigmentosa, and Huntington’s disease. Benitec Biopharma Limited was founded in 1997 and is based in Sydney, Australia.

13 Employees
Last Reported Date: 08/22/14
Founded in 1997

benitec biopharma ltd (BLT) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: A$450.0K
Chief Financial Officer and Company Secretary
Total Annual Compensation: A$267.4K
Chief Business Officer
Total Annual Compensation: A$302.0K
Senior Vice President of Research and Develop...
Total Annual Compensation: A$305.1K
Chief Scientific Officer
Total Annual Compensation: A$225.0K
Compensation as of Fiscal Year 2014.

benitec biopharma ltd (BLT) Key Developments

Benitec Biopharma Limited Announces Third Patient in its Phase I/IIa Clinical Trial of TT-034 for Hepatitis C at the Duke Clinical Research Unit

Benitec Biopharma Limited announced that the third patient in its Phase I/IIa clinical trial of TT-034 for hepatitis C was dosed earlier at the Duke Clinical Research Unit (USA). This is a significant step for this ‘first in man’ study, and follows review of the collective data from the first two patients by the independent Data Safety Monitoring Board (DSMB). The DSMB determined that the patients from the first dosing cohort were clear of any significant treatment-related adverse events. The newly dosed patient is the first to receive the increased dose of TT-034 (1.25 x 10^11 vg/kg, a concentration that is a half log higher than the doses administered in the first cohort). While TT-034 is designed as a potential ‘one-shot’ cure for hepatitis C, the current dose is still below that expected to inhibit viral replication and data from the second dosing cohort are therefore expected to serve primarily as a further safety assessment. As with previous patients, the newly dosed patient will be monitored for six weeks and results will be reviewed by the DSMB. Should the results indicate appropriate safety outcomes, the DSMB is expected to recommend that the remaining two patients in the second cohort be dosed. It is aimed to dose both at approximately the same time. The trial sites at Duke Clinical Research Unit and University of California San Diego have identified a number of patients who have passed initial screening who can be prepared in anticipation of this outcome. TT-034 is a ddRNAi-based therapeutic, designed to treat and potentially cure hepatitis C (HCV) with a single administration. TT-034 targets the hepatitis C viral RNA at three separate, highly conserved sites. As such it acts as a ‘triple therapy’ even though it is a monotherapy, and minimizes the ability of the virus to mutate and escape the therapy. Once it reaches the liver cells, it enters the nucleus and produces three separate short hairpin RNAs continuously for the lifetime of the cell. Thus TT-034 has the potential to not only treat the existing HCV infection, but also to guard against reinfection for months to years without the need to re-treat. TT-034 safety and efficacy has been tested extensively in pre-clinical in vivo studies with no adverse effects observed at therapeutic doses.

Benitec Biopharma Limited Presents at 7th annual Biotech Showcase Conference 2015, Jan-14-2015 04:30 PM

Benitec Biopharma Limited Presents at 7th annual Biotech Showcase Conference 2015, Jan-14-2015 04:30 PM. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

Benitec Biopharma Limited Appoints Claudia Kloth as its Vice President of Manufacturing

Benitec Biopharma Limited announced the appointment of Dr. Claudia Kloth as its Vice President of Manufacturing. Dr. Kloth has more than 14 years of experience in process development and cGMP manufacturing, most recently with gene therapy vectors, including adeno-associated viruses (AAV), which are being used by Benitec in the company's hepatitis C (HCV), hepatitis B (HBV) and age-related macular degeneration (AMD) programs. Dr. Kloth previously led Lonza's process development group in the successful development, optimization, and transfer of robust, viral-based (adenovirus, AAV, lentivirus) and cell therapy products to cGMP manufacturing, through newly established scalable processes. Dr. Kloth is based in the United States and will commence her role with Benitec on 5 January 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BLT:AU A$0.76 AUD -0.02

BLT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Galena Biopharma Inc $1.65 USD -0.06
Marina Biotech Inc $0.62 USD -0.0448
Prosensa Holding NV $18.73 USD -0.06
Silence Therapeutics PLC 222.50 GBp -1.50
Tekmira Pharmaceuticals Corp C$31.85 CAD -0.75
View Industry Companies
 

Industry Analysis

BLT

Industry Average

Valuation BLT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 48.3x
Price/Book 2.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 31.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BENITEC BIOPHARMA LTD, please visit www.benitec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.